Corbus Pharmaceuticals (CRBP) shares slumped 10% in recent trading Friday despite reporting what it described as encouraging data from the "Western" clinical trial of its CRB-701 anti-body drug conjugate.
A total of 26 patients with metastatic urothelial cancer and other solid tumors associated with Nectin-4 expression were evaluable at December 2024 data cut point in the US and UK study.
The phase 1 Western dose escalation study's results mirrored those from the China study in terms of safety, tolerability, and pharmacokinetics, the company said. No dose-limiting adverse events were reported from both studies, it said.
However, Corbus reported one response in four metastatic urothelial cancer patients dosed in the Western study, compared with the China study's 44% involving nine patients.
The company on Friday presented the data from the Western study at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Price: 8.53, Change: -0.95, Percent Change: -10.02
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。